PDCD1 and colorectal carcinoma: Current immune checkpoint blockade therapies have shown positive patient responses against programmed cell death protein-1 (PD-1), with blocking antibodies such as pembrolizumab and nivolumab being food and drug administration (FDA) approved for treatment in metastatic CRC patients with significant microsatellite instability (MSI) mutations [3].